Last reviewed · How we verify
Dexamethasone Ophthalmic Insert
Dexamethasone Ophthalmic Insert is a Corticosteroid Small molecule drug developed by The Cleveland Clinic. It is currently FDA-approved for Inflammation and pain following ocular surgery, Allergic conjunctivitis, Uveitis. Also known as: DEXTENZA®.
Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors.
Dexamethasone is a corticosteroid that suppresses inflammatory and immune responses in the eye by binding to glucocorticoid receptors. Used for Inflammation and pain following ocular surgery, Allergic conjunctivitis, Uveitis.
At a glance
| Generic name | Dexamethasone Ophthalmic Insert |
|---|---|
| Also known as | DEXTENZA® |
| Sponsor | The Cleveland Clinic |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene production, and suppressing immune cell infiltration and cytokine release. The ophthalmic insert formulation provides sustained, localized delivery of the drug to ocular tissues, maintaining therapeutic levels while minimizing systemic exposure and side effects.
Approved indications
- Inflammation and pain following ocular surgery
- Allergic conjunctivitis
- Uveitis
Common side effects
- Increased intraocular pressure
- Cataract formation (with prolonged use)
- Ocular irritation or discomfort
- Conjunctival hyperemia
Key clinical trials
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes (PHASE4)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
- DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (EARLY_PHASE1)
- In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery (PHASE4)
- Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus (EARLY_PHASE1)
- Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone Ophthalmic Insert CI brief — competitive landscape report
- Dexamethasone Ophthalmic Insert updates RSS · CI watch RSS
- The Cleveland Clinic portfolio CI
Frequently asked questions about Dexamethasone Ophthalmic Insert
What is Dexamethasone Ophthalmic Insert?
How does Dexamethasone Ophthalmic Insert work?
What is Dexamethasone Ophthalmic Insert used for?
Who makes Dexamethasone Ophthalmic Insert?
Is Dexamethasone Ophthalmic Insert also known as anything else?
What drug class is Dexamethasone Ophthalmic Insert in?
What development phase is Dexamethasone Ophthalmic Insert in?
What are the side effects of Dexamethasone Ophthalmic Insert?
What does Dexamethasone Ophthalmic Insert target?
Related
- Drug class: All Corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: The Cleveland Clinic — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Inflammation and pain following ocular surgery
- Indication: Drugs for Allergic conjunctivitis
- Indication: Drugs for Uveitis
- Also known as: DEXTENZA®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing